ReviewEmerging infectious diseases2003
Maintaining fluoroquinolone class efficacy: review of influencing factors.
Review in Emerging infectious diseases, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2003Guideline
- Fluoroquinolone Use and Risk of Pneumothorax in Adults Hospitalized With Community Acquired Pneumonia: A Retrospective Cohort Study.The clinical respiratory journal · 2026Article
- Exploring norfloxacin analogs in combating antimicrobial resistance: design, mechanistic insights and structure activity relationship.Future medicinal chemistry · 2025Review
- The Rise, Fall, and Rethink of (Fluoro)quinolones: A Quick Rundown.Pathogens (Basel, Switzerland) · 2025Review
- Analysis of ESAC-Net/EARS-Net Data from 29 EEA Countries for Spatiotemporal Associations Between Antimicrobial Use and Resistance-Implications for Antimicrobial Stewardship?Antibiotics (Basel, Switzerland) · 2025Article
- Fluoroquinolone-Mediated Tendinopathy and Tendon Rupture.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Using delafloxacin, a 4th generation fluoroquinolone, in combination with nebulised tobramycin to eradicateRespiratory medicine case reports · 2025Article
- Prevalence and Antibiotic Resistance ofLife (Basel, Switzerland) · 2024Article
- Article
- The effect of fluoroquinolones and antioxidans on biofilm formation by Proteus mirabilis strains.Annals of clinical microbiology and antimicrobials · 2022Article
- Biochemical Characterization of New Gemifloxacin Schiff Base (GMFX-o-phdn) Metal Complexes and Evaluation of Their Antimicrobial Activity against Some Phyto- or Human Pathogens.International journal of molecular sciences · 2022Article
- Article
- Different Nanotechnology Approaches for Ciprofloxacin Delivery Against Multidrug-Resistant Microbes.Infection and drug resistance · 2022Review
- Antibacterial Prodrugs to Overcome Bacterial Resistance.Molecules (Basel, Switzerland) · 2020Review
- A Baker's Dozen of Top Antimicrobial Stewardship Intervention Publications in 2018.Open forum infectious diseases · 2019Article
- Exploitation of Antibiotic Resistance as a Novel Drug Target: Development of a β-Lactamase-Activated Antibacterial Prodrug.Journal of medicinal chemistry · 2019Article
- Ubiquitous Nature of Fluoroquinolones: The Oscillation between Antibacterial and Anticancer Activities.Antibiotics (Basel, Switzerland) · 2017Review
- Multiple antibiotic resistance indexing of Escherichia coli to identify high-risk sources of faecal contamination of water.Environmental science and pollution research international · 2015Article
- Repurposing the antihistamine terfenadine for antimicrobial activity against Staphylococcus aureus.Journal of medicinal chemistry · 2014Article
- Bacteria tracking by in vivo magnetic resonance imaging.BMC biology · 2013Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Previous experience with antimicrobial resistance has emphasized the importance of appropriate stewardship of these pharmacotherapeutic agents. The introduction of fluoroquinolones provided potent new drugs directed primarily against gram-negative pathogens, while the newer members of this class demonstrate more activity against gram-positive species, including Streptococcus pneumoniae. Although these agents are clinically effective against a broad range of infectious agents, emergence of resistance and associated clinical failures have prompted reexamination of their use. Appropriate use revolves around two key objectives: 1) only prescribing antimicrobial therapy when it is beneficial and 2) using the agents with optimal activity against the expected pathogens. Pharmacodynamic principles and properties can be applied to achieve the latter objective when prescribing agents belonging to the fluoroquinolone class. A focused approach emphasizing "correct-spectrum" coverage may reduce development of antimicrobial resistance and maintain class efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.